The combination of body mass index and serum creatinine levels predicts survival in patients with Hodgkin lymphoma treated with nivolumab in the CheckMate 205 study.

Patients with solid tumors and a higher body mass index (BMI) experience improved survival after receiving anti-PD1 antibodies. The predictive role of BMI in Hodgkin Lymphoma (HL), the most sensitive malignancy to PD1-blockade, remains unclear. We analyzed the association between BMI and survival outcomes in patients treated with the anti-PD-1 antibody nivolumab within the CheckMate 205 study. Patients with a lower BMI (<24.03 kg/m) had a longer progression-free survival (PFS) (46.4% at three years) than those with a higher BMI (≥24.03 kg/m;19.6%;  = 0.03). Combining the BMI cutoff with serum creatinine (sCr) levels generated a variable (BMCI) stratifying patients into distinct PFS risk groups. Patients with a BMCI (BMI ≥24.03 kg/m/sCr <0.7 mg/dL) displayed a threefold increased PFS risk (95% CI,1.6-5.7;  < 0.001) than those with a BMCI (BMI <24.03 kg/m/sCr ≥0.7 mg/dL). In a separate analysis of pretreated patients, those with a BMCI had a PFS risk 3.5-fold higher (95% CI,1.9-6.6;  < 0.001) than patients with a BMCI. The BMCI maintained its independent significance in a multivariable model including attenuating factors and predictive biomarkers. HL patients with reduced BMI but preserved lean body mass (BMCI) exhibit a more favorable response to nivolumab. Results highlight an unexpected side of the 'obesity paradox' in HL.